MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $36.29 (65.16% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Piper JaffrayReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Needham & Company LLCReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Jefferies GroupReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016BarclaysLower Price TargetEqual Weight$42.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cowen and CompanyReiterated RatingOutperform -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Leerink SwannLower Price TargetMarket Perform$40.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$65.00 -> $48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015Deutsche BankSet Price TargetBuy$78.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Janney Montgomery ScottInitiated CoverageNeutral -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Stifel NicolausDowngradeBuy -> Hold$66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014LaidlawBoost Price Target$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.45)($0.45)($0.45)
Q3 20161($0.51)($0.51)($0.51)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)
Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline
06/23/16 05:00 PMOrexigen Therapeutics, (NASDAQ:OREX) & Ionis Pharmaceuticals (NASDAQ:IONS) Healthcare Stocks on Trader's Radar - Wall Street 24
06/22/16 11:49 AMIonis Pharmaceuticals to Host R&D Day - [at noodls] - CARLSBAD, Calif., June 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will host an R&D Day on Wednesday, July 13 at 8:00 a.m. Eastern Time at The London ...
06/16/16 08:55 AMJim Cramer Tries To Limit Risk On Ionis Pharmaceuticals And Sarepta Therapeutics
06/15/16 04:42 PMValuable Analysts Trends to Observe: Johnson & Johnson (JNJ) , Ionis Pharmaceuticals (IONS) - Street Updates
06/15/16 04:42 PMPreview of Analysts Recommendation: St. Jude Medical, Inc. (NYSE:STJ) , Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Street Updates
06/09/16 04:53 PMAnalysts Reviewing Stocks: Boston Scientific Corporation (NYSE:BSX) , Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Street Updates
06/09/16 04:53 PMStock to Track: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - News Oracle
06/09/16 04:53 PMIonis Pharmaceuticals (IONS): Today's Weak On High Volume Stock - TheStreet.com
06/09/16 07:22 AMMost Active Stocks Update: Las Vegas Sands Corp. (NYSE:LVS), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Beacon Chronicle
06/09/16 07:22 AMHC Stocks Updates: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Dermira Inc (NASDAQ:DERM) - share market updates (press release)
06/08/16 04:56 PMWorthy Stock Update: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - News Oracle
06/08/16 07:25 AMHC Stocks Midpoint: Ionis Pharmaceuticals Inc (NASDAQ:IONS), AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release)
06/07/16 04:49 PMEarnings Overview of the Stocks: Monster Beverage Corporation (NASDAQ:MNST), Ionis Pharmaceuticals, Inc ... - Beacon Chronicle
06/07/16 04:49 PMEarnings Overview of the Stocks: Monster Beverage Corporation (NASDAQ:MNST), Ionis Pharmaceuticals, Inc ... - Beacon Chronicle
06/07/16 04:49 PMIonis Shareholders Cannot Catch A Break - Seeking Alpha
06/07/16 04:49 PMIonis Shareholders Cannot Catch A Break - Seeking Alpha
06/06/16 04:35 PMTwo Buzzers within Analysts Radar: Abbott Laboratories (NYSE:ABT) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Street Updates
06/06/16 04:35 PMInvestor Catching Stock: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - News Oracle
06/06/16 04:35 PMEarnings Overview: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Newell Brands Inc. (NYSE:NWL) - Beacon Chronicle
06/06/16 08:14 AMHC Stocks Assessments: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Anacor Pharmaceuticals Inc (NASDAQ:ANAC) - share market updates (press release)
06/05/16 07:21 AMIonis Pharmaceuticals' (IONS) “Buy” Rating Reiterated at Cowen and Company - Let Me Know About This
06/03/16 05:00 PMStocks Earnings Analysis Report: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Spirit Realty Capital, Inc. (NYSE:SRC) - Beacon Chronicle
06/03/16 05:00 PMIonis Pharmaceuticals, Inc. Was Pummeled in May -- Here's Why - Motley Fool
06/03/16 07:20 AMHC Sector News Alert: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) - share market updates (press release)HC Sector News Alert: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Ionis Pharmaceuticals Inc (NASDAQ:IONS)share market updates (press release)Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) ended Thursday session in green amid volatile trading. The shares closed up +4.12 points or 4.71% at $91.52 with 1.95 million shares getting traded. Post opening the session at $89.04, the shares ...and more »
06/03/16 07:20 AMUpdated Analysts Rating Report: Merck & Company, Inc. (NYSE:MRK) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Street Updates - Updated Analysts Rating Report: Merck & Company, Inc. (NYSE:MRK) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Street UpdatesIonis Pharmaceuticals, Inc. (NASDAQ:IONS) after beginning at $22.55, closed at $23.75 by building up +5.46% in recent trading session. Most recent session's volume of 3.11 million shares greater than its average volume of 2.35 million shares. The ...and more »
06/02/16 04:54 PMHave a look at Analyst Actions: Gilead Sciences, Inc. (NASDAQ:GILD) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Street Updates - Seeking AlphaHave a look at Analyst Actions: Gilead Sciences, Inc. (NASDAQ:GILD) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Street UpdatesIonis Pharmaceuticals, Inc. (NASDAQ:IONS) showed bearish move with loss of -0.75% after exchanging volume of 3.43 million shares in last trading session ended on 6/1/2016. The company recent traded volume was higher than its average volume of 2.33 ...How Much More Time Will Investors Give Gilead?Seeking Alphaall 75 news articles »
06/02/16 04:54 PMBest Stocks to Buy: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), The Chemours Company (NYSE:CC) - Beacon Chronicle - Beacon ChronicleBest Stocks to Buy: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), The Chemours Company (NYSE:CC)Beacon ChronicleLast Trade: The Company closed its last session at $22.52 with the loss of -0.75%. The market capitalization of the company is $2.72 Billion, with the average Volume of 2.3 Million. The stock currently has its 52-Week High range of $71.5 and 52-week ...and more »
06/02/16 07:26 AMHC Sector News Alert: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Baxter International Inc (NYSE:BAX) - share market updates (press release) - share market updates (press release)HC Sector News Alert: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Baxter International Inc (NYSE:BAX)share market updates (press release)Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) ended Wednesday session in red amid volatile trading. The shares closed down -0.17 points or -0.75% at $22.52 with 3.43 million shares getting traded. Post opening the session at $22.57, the shares hit ...Healthcare Stock's Buzzers: Ionis Pharmaceuticals Inc(NASDAQ:IONS), Amarin Corporation plc (ADR)(NASDAQ:AMRN)NYSE Journal (press release)Two Healthcare stocks to Focus: Ionis Pharmaceuticals Inc (NASDAQ:IONS) , Alexion Pharmaceuticals, Inc. (NASDAQ ...Is storiesIonis Pharmaceuticals Inc (IONS) Reaches New 1-Year Low Following Analyst DowngradeLet Me Know About ThisRisers & Fallers -Street Updates -KC Registerall 20 news articles »
06/01/16 04:58 PMHealthcare Stock's Buzzers: Ionis Pharmaceuticals Inc(NASDAQ:IONS), Amarin Corporation plc (ADR)(NASDAQ:AMRN) - NYSE Journal (press release) - Healthcare Stock's Buzzers: Ionis Pharmaceuticals Inc(NASDAQ:IONS), Amarin Corporation plc (ADR)(NASDAQ:AMRN)NYSE Journal (press release)On Tuesday, Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS), added 3.11% and closed at $22.69 in the last trading session. The last trading range of the stock ranges between $21.71 and $23.18. May 26, 2016 – Ionis Pharmaceuticals, Inc. (IONS) ...and more »
06/01/16 03:06 PMAlkermes Rises on Evercore’s ‘Buy’ Rating, Buying Support -
06/01/16 07:26 AMHC Stocks Watchful: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Baxter International Inc (NYSE:BAX) - share market updates (press release) - HC Stocks Watchful: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Baxter International Inc (NYSE:BAX)share market updates (press release)Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) ended Tuesday session in green amid volatile trading. The shares closed up +0.69 points or 3.11% at $22.69 with 5.91 million shares getting traded. Post opening the session at $22.29, the shares hit an ...and more »
06/01/16 07:26 AMAnalysts Rating Overview: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Updates - Analysts Rating Overview: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH)Street UpdatesAnalysts Rating Overview: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - The following two tabs change content below.BioLatest Posts admin Latest posts by admin (see all) Analysts Rating updates about two ...and more »
05/31/16 09:01 AMMid Cap Volatile Stocks: Veeva Systems Inc. (NYSE:VEEV), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Globalstar ... - KC Register - Mid Cap Volatile Stocks: Veeva Systems Inc. (NYSE:VEEV), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Globalstar ...KC RegisterIonis Pharmaceuticals, Inc. (NASDAQ:IONS) traded 9.16 Million shares and its share price increased 3.02% to close at $22.00. Company has 0.10% insider ownership. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) quarterly performance is -36.33% while its ...and more »
05/31/16 09:01 AMBetter Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc. - Motley Fool - Seeking AlphaBetter Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.Motley FoolIonis Pharmaceuticals, Inc. (NASDAQ:IONS) doesn't look much better, with a drop of nearly 70% during the same period. Despite the nasty declines recently, one of these stocks just might be a good pick at its current price. Which biotech is the better buy?Ionis Investors And Management Should Focus On Success In NeurologySeeking Alphaall 4 news articles »
05/29/16 09:20 AM5 Companies That Destroyed Shareholders Last Week -
05/28/16 10:02 AMMinerva Neurosciences (NASDAQ:NERV) & Ionis Pharmaceuticals (NASDAQ:IONS) are Hot Healthcare Stocks - Wall Street 24 - Minerva Neurosciences (NASDAQ:NERV) & Ionis Pharmaceuticals (NASDAQ:IONS) are Hot Healthcare StocksWall Street 24On Thursday, Shares of Minerva Neurosciences Inc (NASDAQ:NERV) gained 233.33% to $11.80. The share price is trading in a range of $8.26 – $13.22. The stock exchanged hands with 33.16 Million shares contrast to its average daily volume of 88,803 ...and more »
05/28/16 10:02 AMAnalyst Update: Ionis Pharmaceuticals Inc, Splunk Inc, and Trina Solar Limited - Schaeffers Research (blog) - Schaeffers Research (blog)Analyst Update: Ionis Pharmaceuticals Inc, Splunk Inc, and Trina Solar LimitedSchaeffers Research (blog)Analysts are weighing in on drugmaker Ionis Pharmaceuticals Inc (NASDAQ:IONS), tech stock Splunk Inc (NASDAQ:SPLK), and alternative energy issue Trina Solar Limited (ADR) (NYSE:TSL). Here's a quick roundup of today's brokerage notes on IONS, ...and more »
05/27/16 03:25 PMBMO Downgrades Ionis Pharma After Platelet Concerns Spill Over To Volanesorsen - Shares of Ionis Pharmaceuticals Inc (NASDAQ: IONS) lost 39.42 percent on Thursday after the company announced that GlaxoSmithKline plc (ADR) (NYSE: GSK), which has the option to license the company’s IONIS-TTRx — currently undergoing a Phase 3 trial, has decided not to initiate a Stage 3 trial for CARDIO-TTR until there’re data from the NEURO-TTR and investigator-sponsored Phase II aTTR cardiomyopathy studies available. Following said event, BMO Capital Markets analyst Do Kim decided to downgrade the stock from Outperform to Market Perform, while trimming the firm’s price target from $55 to $26, as the ...Full story available on Benzinga.com
05/27/16 11:09 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals Inc. (NASDAQ: IONS ... - Markets.co - Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals Inc. (NASDAQ: IONS ...Markets.coCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals Inc. (NASDAQ: IONS), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Cempra (NASDAQ: CEMP) and Immune Design Corp (NASDAQ: ...
05/27/16 11:09 AMAnalyst Opinion of: Ionis Pharmaceuticals Inc (IONS), Ford Motor Company (F) - News Oracle - Analyst Opinion of: Ionis Pharmaceuticals Inc (IONS), Ford Motor Company (F)News OracleThe stock declined -39.42% and closed its last session at $21.36. The Company has the market capitalization of 2.73 Billion. The 52-Week Range ranges between $21.09 and $71.50. The stock traded with the Volume of 27.20 Million in the last trading day ...and more »
05/27/16 11:09 AMIonis Pharmaceuticals Inc (IONS) Got Killed Yesterday: Here's Why - LearnBonds - LearnBondsIonis Pharmaceuticals Inc (IONS) Got Killed Yesterday: Here's WhyLearnBondsShares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) are trading in red after the company announced that GlaxoSmithKline plc (ADR) (NYSE:GSK), which has an option to exclusively license IONIS-TTR Rx, will not initiate the phase 3 study, CARDIO-TTR.Ionis Pharmaceuticals Inc (IONS) Plunges After GSK Foregos Phase 3 Study of TTRRxInsider Monkey (blog)Ionis Pharmaceuticals' (IONS) "Hold" Rating Reiterated at Cowen and CompanyThe Cerbat GemIonis Pharmaceuticals Inc. (IONS) Is Sinking After GSK Decides Against Phase 3RTT NewsZergwatch -share market updates (press release) -Seneca Globeall 63 news articles »
05/27/16 09:45 AMIonis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans -
05/27/16 08:33 AMIonis Pharmaceuticals (IONS) Stock Falls, BMO Downgrades on GlaxoSmithKline Trial Delay -
05/27/16 07:01 AMTrending Now: IONS -
05/26/16 05:17 PMWhy Abercrombie & Fitch Co. (ANF), Carnival Corp (CCL) and Ionis Pharmaceuticals Inc (IONS) Are 3 of Today’s Worst Stocks - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Abercrombie & Fitch (ANF), Carnival (CCL), Ionis Pharmaceuticals (IONS) were doomed from the start of Thursday's trading.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/05/why-abercrombie-fitch-co-anf-carnival-corp-ccl-and-ionis-pharmaceuticals-inc-ions-are-3-of-todays-worst-stocks/">Why Abercrombie & Fitch Co. (ANF), Carnival Corp (CCL) and Ionis Pharmaceuticals Inc (IONS) Are 3 of Today’s Worst Stocks</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
05/26/16 04:52 PMUPDATE 1-Ionis shares plummet as GSK scraps heart drug trial plans - May 26 (Reuters) - Ionis Pharmaceuticals Inc's shares plunged 40 percent on Thursday, wiping out over $900 million from its market value, after the company said GlaxoSmithKline Plc had scrapped...
05/26/16 03:51 PMWhy Abercrombie & Fitch Co. (ANF), Carnival Corp (CCL) and Ionis Pharmaceuticals Inc (IONS) Are 3 of Today’s Worst Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Abercrombie & Fitch (ANF), Carnival (CCL), Ionis Pharmaceuticals (IONS) were doomed from the start of Thursday's trading. The post Why Abercrombie & Fitch Co. (ANF), Carnival Corp (CCL) and Ionis Pharmaceuticals Inc (IONS) Are 3 of Today’s Worst Stocks appeared first on InvestorPlace.
05/26/16 02:52 PMIonis shares slump 40 pct as GSK scraps heart drug trial plans - May 26 (Reuters) - Ionis Pharmaceuticals Inc's shares plunged 40 percent on Thursday, wiping out over $900 million from its market value, after the company said GlaxoSmithKline Plc had scrapped...
05/26/16 11:26 AMIonis Pharmaceuticals Drops on Dismissed Study -
05/26/16 10:12 AMHealthcare Stocks to Watch Johnson & Johnson (NYSE:JNJ), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - NYSE Journal (press release) - Healthcare Stocks to Watch Johnson & Johnson (NYSE:JNJ), Ionis Pharmaceuticals Inc (NASDAQ:IONS)NYSE Journal (press release)On Wednesday, Shares of Johnson & Johnson (NYSE:JNJ), added 0.57% and closed at $113.33 in the last trading session. The last trading range of the stock ranges between $112.85 and $113.72. Johnson & Johnson (JNJ) will take part in the Goldman ...and more »
About Ionis Pharmaceuticals

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases, including cardiovascular; metabolic; severe and rare diseases, including neurological disorders, and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs, nusinersen, volanesorsen and IONIS-TTR to the market. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen, IONIS-DMPK-2.5, Plazomicin and IONIS-GCGR.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IONS
  • CUSIP: 46433010
Key Metrics:
  • Previous Close: $21.97
  • 50 Day Moving Average: $27.17
  • 200 Day Moving Average: $39.70
  • P/E Ratio: N/A
  • P/E Growth: -0.39
  • Market Cap: $2.65B
  • Current Quarter EPS Consensus Estimate: $-1.49 EPS
Additional Links:
Ionis Pharmaceuticals (NASDAQ:IONS) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha